All news


First-of-its-kind, patient-activated, pre-filled injector (PFI) to deliver pegfilgrastim (Pelgraz▼) approved in Europe

Pelgraz is the market-leading biosimilar pegfilgrastim in Ireland

The European Medicines Agency (EMA) has approved Accord’s Pelgraz (pegfilgrastim 6 mg), pegylated granulocyte-colony stimulating factor (G-CSF) pre-filled injector (PFI) indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia for adult patients undergoing cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). The Pelgraz PFI® device contains a hidden needle and delivers one dose of pegfilgrastim, which patients can self-administer from the comfort of their own homes.

With a one-dose-per-chemotherapy cycle regime that patients can self-administer, Pelgraz PFI provides physicians with a patient friendly way to reduce the incidence of febrile neutropenia during their chemotherapy treatment regimen.

“Evidence shows that travelling to and attending hospital visits are one of the major contributing factors that negatively impact the quality of life for people living with cancer. Reducing the number of times that a patient must visit the clinic or hospital, at a time when they are living with the side-effects of chemotherapy and when their immune systems are compromised, must be a priority for patients and their healthcare team.  Being able to offer the option of spending more time at home during chemotherapy treatment is something I know patients genuinely welcome and also means that the clinic could potentially make more effective use of nurse resources.” said Prof Hartmut Link, Professor of Medicine, external faculty at University Medical Centre, Hannover, Germany.

Paul Tredwell, Accord VP Speciality Brands, EMENA said “Accord’s ongoing purpose is to find ways to make it better for patients; to find innovative solutions that go beyond the original offering to not only deliver positive patient outcomes, but also improve patients’ experience of our treatments.” 

Patients prescribed Pelgraz PFI will receive support materials including digital services to guide them through administration, providing reassuring support for both patients and their healthcare team.

Pelgraz PFI is the latest addition to Accord’s established portfolio of over 30 oncology and oncology related treatments across Europe. Accord will manufacture Pelgraz PFI in its own state-of-the-art production facility.


All news